uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
María Angeles López Sánchez(Vall d'Hebron Institut de Recerca), María del Mar Mañú‐Pereira(Vall d'Hebron Institut de Recerca), Emma Drašar(Whittington Health NHS Trust), Marta Morado‐Arias(Hospital Universitario La Paz), Elena Cela(Universidad Complutense de Madrid), Monika Horváthová(Palacký University Olomouc), Anna Collado Gimbert(Vall d'Hebron Institut de Recerca), Petros Kountouris(Cyprus Institute of Neurology and Genetics), Victoria Gutiérrez Valle(Vall d'Hebron Institut de Recerca), Andreas E. Kulozik(Heidelberg University), Stella Tamana(Fundación Instituto Leloir), Joachim B. Kunz(Heidelberg University), Minke A.E. Rab(Utrecht University), Paola Bianchi(University of Pavia), Celeste Bento(Hospitais da Universidade de Coimbra), Sara Reidel(Vall d'Hebron Institut de Recerca), Richard van Wijk(Utrecht University), Frederic Galactéros(Inserm), Patricia Aguilar‐Martinez(Centre Hospitalier Universitaire de Montpellier), Noémi Roy(John Radcliffe Hospital), Raffaella Colombatti(University of Padua), Sarah Wambacq(Queen Fabiola Children's University Hospital), Laurence Dedeken(Université Libre de Bruxelles), Béatrice Gulbis(Université Libre de Bruxelles), Dagmar Pospı́šilová(Palacký University Olomouc), Andreas Glenthoej(Copenhagen University Hospital), Ana Ortuno Cabrero(Whittington Hospital), Pavla Kořalková(Palacký University Olomouc), Claire Diot(Vall d'Hebron Institut de Recerca), Eduard J. van Beers(Utrecht University)
Cited by 0
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Critical assessment of protein intrinsic disorder prediction
|Nature Methods|2021|362
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2018|304
Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies
|Journal of Clinical Virology|2020|298